Literature DB >> 18410900

IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.

L Lee Dupuis1, Cathryn Sibbald, Tal Schechter, Marc Ansari, Adam Gassas, Yves Théorêt, Nastya Kassir, Martin A Champagne, John Doyle.   

Abstract

We currently calculate area under the busulfan concentration time curve (AUC) using 7 plasma busulfan concentrations (AUC7) drawn after the first of 16 i.v. busulfan doses given as a 2-hour infusion every 6 hours. The aim of this study was to develop and validate limited sampling strategies (LSSs) using 3 or fewer busulfan concentration values with which to reliably calculate AUC in children undergoing hematopoietic stem cell transplant (HSCT). Children in the development group (44) received i.v. busulfan at Sick Kids; the validation group consisted of 35 children who received care at CHU Ste-Justine. Busulfan doses given and subsequent plasma busulfan concentrations were recorded. LSSs using 1 to 3 concentration-time points were developed using multiple linear regression. LSS were considered to be acceptable when adjusted r(2) > 0.9, mean bias <15% and precision <15%. Extent of agreement between the AUC7 values and the LSS AUC was assessed by the intraclass correlation coefficient (ICC) and Bland-Altman (BA) analysis. Agreement was considered to be excellent when the lower limit of the 95% confidence limit of the ICC exceeded 0.9 and when the limits of agreement in the BA analysis were +/-15% for both AUC and dose. Administration of the theoretic adjusted busulfan doses based on each LSS was simulated and cases where the resulting AUC was >1500 or <900 microM x min were noted. LSSs using 1, 2, or 3 plasma busulfan concentrations were developed that showed excellent agreement with AUC7 and adjusted busulfan doses. In the validation sample, only the 2- and 3-point LSSs demonstrated acceptable precision and lack of bias. LSSs using 2 or 3 plasma busulfan concentrations can be used to reliably estimate busulfan AUC after IV administration in children undergoing HSCT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410900     DOI: 10.1016/j.bbmt.2008.03.002

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  6 in total

1.  Limited sampling strategy models for estimating the AUC of gliclazide in Chinese healthy volunteers.

Authors:  Ji-Han Huang; Kun Wang; Xiao-Hui Huang; Ying-Chun He; Lu-Jin Li; Yu-Cheng Sheng; Juan Yang; Qing-Shan Zheng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-05-26       Impact factor: 2.441

2.  Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.

Authors:  Erika Watanabe; Takuro Nishikawa; Kazuro Ikawa; Hiroki Yamaguchi; Takanari Abematsu; Shunsuke Nakagawa; Koichiro Kurauchi; Yuichi Kodama; Takayuki Tanabe; Yuichi Shinkoda; Kazuaki Matsumoto; Yasuhiro Okamoto; Yasuo Takeda; Yoshifumi Kawano
Journal:  Int J Hematol       Date:  2015-08-05       Impact factor: 2.490

3.  Accurately Achieving Target Busulfan Exposure in Children and Adolescents With Very Limited Sampling and the BestDose Software.

Authors:  Michael Neely; Michael Philippe; Teresa Rushing; Xiaowei Fu; Michael van Guilder; David Bayard; Alan Schumitzky; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Ther Drug Monit       Date:  2016-06       Impact factor: 3.681

4.  Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation.

Authors:  Rachael Lawson; Lachlan Paterson; Christopher J Fraser; Stefanie Hennig
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-22       Impact factor: 3.333

5.  The clinical relevance of pre-formed anti-HLA and anti-MICA antibodies after cord blood transplantation in children.

Authors:  Marc Ansari; Chakradhara Rao S Uppugunduri; Sylvie Ferrari-Lacraz; Henrique Bittencourt; Fabienne Gumy-Pause; Yves Chalandon; Jean-Marie Tiercy; Tal Schechter; Adam Gassas; John D Doyle; Lee Dupuis; Michel Duval; Maja Krajinovic; Jean Villard
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

6.  Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.

Authors:  Joy Benadiba; Marc Ansari; Maja Krajinovic; Marie-France Vachon; Michel Duval; Pierre Teira; Sonia Cellot; Henrique Bittencourt
Journal:  PLoS One       Date:  2018-04-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.